Lancet Neurology:亨廷顿病进展相关的基因突变

2017-06-20 zhangfan MedSci原创

研究发现了与亨廷顿病进展相关的基因突变,该基因对疾病的进展预测具有较高的敏感性

亨廷顿病是由在亨廷顿基因的CAG重复扩张引起的。一段时间内发病年龄被用来作为遗传分析的定量表型,这种分类方法无益于疾病的认识和治疗。近日研究人员通过遗传标记法确定新的疾病进展指标。

研究人员对218名亨廷顿基因携带者进行前瞻性纵向变化的累进评分并在建立了含1773名患者的对照集,对216位试验参与者和1773名对照者进行全基因组关联分析并对结果进行了荟萃分析。

研究发现,研究组与对照集患者纵向运动、认知和影像学评分相互关联,研究组与对照集患者疾病进展相互关联(r=0.674)。荟萃分析发现,两组患者5号染色体中的3个基因存在异常:MSH3, DHFR和MTRNR2L2。在研究组中3个基因与疾病进展相关(MSH3 p=2.94×10-8 DHFR p=8.37×10-7 MTRNR2L2 p=2.15×10-9),但与对照集相关性较低(MSH3 p=9.36×10-4 DHFR p=8.45×10-4 MTRNR2L2 p=1.20×10-3)。rs557874766基因在全基因组荟萃分析中意义重大(p=1.58×10-8)导致MSH3编码一个氨基酸的变化并导致患者亨廷顿病综合评分平均每年0.4分的减少(95% CI 0.16-0.66)以及总功能评分每年0.12分减少(95% CI 0.06-0.18),该相关性在根据患者年龄调整后依然显著。

研究发现了与亨廷顿病进展相关的基因突变,该基因对疾病的进展预测具有较高的敏感性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829027, encodeId=90fc182902e91, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 14 22:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999991, encodeId=55dc199999101, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jan 26 14:18:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365097, encodeId=5736136509eb5, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622749, encodeId=306f1622e49d6, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213135, encodeId=5f7321313531, content=认真学习,提高业务, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Tue Jun 20 13:29:11 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-12-14 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829027, encodeId=90fc182902e91, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 14 22:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999991, encodeId=55dc199999101, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jan 26 14:18:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365097, encodeId=5736136509eb5, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622749, encodeId=306f1622e49d6, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213135, encodeId=5f7321313531, content=认真学习,提高业务, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Tue Jun 20 13:29:11 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2018-01-26 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829027, encodeId=90fc182902e91, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 14 22:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999991, encodeId=55dc199999101, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jan 26 14:18:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365097, encodeId=5736136509eb5, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622749, encodeId=306f1622e49d6, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213135, encodeId=5f7321313531, content=认真学习,提高业务, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Tue Jun 20 13:29:11 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829027, encodeId=90fc182902e91, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 14 22:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999991, encodeId=55dc199999101, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jan 26 14:18:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365097, encodeId=5736136509eb5, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622749, encodeId=306f1622e49d6, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213135, encodeId=5f7321313531, content=认真学习,提高业务, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Tue Jun 20 13:29:11 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1829027, encodeId=90fc182902e91, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 14 22:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999991, encodeId=55dc199999101, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jan 26 14:18:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365097, encodeId=5736136509eb5, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622749, encodeId=306f1622e49d6, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 01:18:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213135, encodeId=5f7321313531, content=认真学习,提高业务, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Tue Jun 20 13:29:11 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 1e1a50a1m36(暂无匿称)

    认真学习,提高业务

    0

相关资讯

Lancet Neuro:亨廷顿症治疗药PBT2的临床Ⅱ期研究

PBT2是一种金属蛋白衰减复合物,在亨廷顿症小鼠模型中,可以减少金属离子诱导的亨廷顿突变蛋白的聚集,并且延长小鼠寿命。研究人员在一项随机、双盲、安慰剂对照的临床Ⅱ期试验中,评估了PBT2对亨廷顿症的疗效和安全性。 研究方法: 在这项为期26周、双盲、安慰剂对照临床试验中,患有轻、中度亨廷顿症的受试者(年龄 · 2014-11-22

-->

JAMA:Deutetrabenazine对亨廷顿病患者舞蹈病样症状的改善有效

Deutetrabenazine是一种新型的含氘分子,可使CYP2D6代谢减弱,增加活性代谢物的半衰期,因此有可能形成稳定的全身暴露,而保持关键部位的药理活性。

Neurology:Pridopidine治疗亨廷顿病安全性和耐受性均较好

  欧洲学者的一项研究表明,在亨廷顿病患者中pridopidine通常安全且耐受性良好。论文于2013年2月27日在线发表于《神经病学》(Neurology)。   此项研究分为6个月随机对照试验(RCT)和6个月开放标签扩展试验(OLE)两个阶段。在OLE阶段,亨廷顿病患者接受4周pridopidine 45mg/天治疗后再接受22周90 mg/天治疗。对任何不良事件(AE

干细胞移植有望治疗亨廷顿病

       经过5年多潜心研究,复旦大学上海医学院解剖与组织胚胎学系青年教师马丽香在***、复旦大学特聘教授张素春博士指导下,发现了来源于人胚胎干细胞的GABA能神经细胞可以修复运动障碍,对治疗人类亨廷顿病有重要意义。该成果已在线发表在3月16日国际顶尖学术期刊《细胞》的子刊《细胞—干细胞》(Cell Stem Cell )杂志上。           研究发现,亨廷顿病产生原因是由于GABA能神经细胞逐步退

Neurology:亨廷顿病风险基因远比你想象中的更常见

亨廷顿病(HD)是一种遗传性神经退行性疾病,据估计约30000多美国人患有此病,此外,还有200000人存在患病风险。但是,据来自加拿大温哥华英属哥伦比亚大学的一项新的研究显示,实际上的人数远比上述估计的要多,该研究发现已发表于Neurology。研究人员发现,普通人群体中“较低的外显率”(引起HD的基因突变的拷贝数为36-39)的发生率较既往报告的更大。这意味着,HD发生低危风险的患者的数目可能

干细胞移植有望治疗亨廷顿病

经过5年多潜心研究,复旦大学上海医学院解剖与组织胚胎学系青年教师马丽香在***、复旦大学特聘教授张素春博士指导下,发现了来源于人胚胎干细胞的GABA能神经细胞可以修复运动障碍,对治疗人类亨廷顿病有重要意义。该成果已在线发表在3月16日国际顶尖学术期刊《细胞》的子刊《细胞—干细胞》(Cell Stem Cell )杂志上。 

 
· 2012-03-22

-->